Shots:
- Regeneron has entered into a global collaboration with Tessera Therapeutics to develop & commercialize TSRA-196 as a one-time gene editing treatment of AATD
- As per the deal, Tessera & Regeneron will equally share global development costs & potential future profits for TSRA-196. Tessera will receive $150M in upfront & equity investment plus $125M in near & mid-term milestones, with Tessera leading the first-in-human trial, & Regeneron handling later development & commercialization
- Additionally, Tessera is planning to file an IND & multiple clinical trial applications for TSRA-196 with the US FDA by year-end
Ref: Regeneron | Image: Regeneron and Tessera Therapeutics | Press Release
Related News: Regeneron and Sanofi Report the EC Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
